Prevalence and Trends in Systemic Treatment for Pediatric Psoriasis in the USA between 2015 and 2021.

IF 4.2 3区医学 Q1 DERMATOLOGY

Dermatology and Therapy Pub Date : 2025-09-26 DOI:10.1007/s13555-025-01545-5

Anna Ramond, Theresa Rosario-Jansen, Xinyu Yang, Amy S Paller

{"title":"Prevalence and Trends in Systemic Treatment for Pediatric Psoriasis in the USA between 2015 and 2021.","authors":"Anna Ramond, Theresa Rosario-Jansen, Xinyu Yang, Amy S Paller","doi":"10.1007/s13555-025-01545-5","DOIUrl":null,"url":null,"abstract":"Introduction: Biologics may have altered the standard of care for pediatric psoriasis, the prevalence of which has not been studied since 2015. The objective of this study was to provide an update of the prevalence of and treatment landscape for pediatric psoriasis in the USA, highlighting the current burden of the condition and the need for improved disease awareness.Methods: In this retrospective cohort study, US claims data (July 2015 to October 2021) from the MarketScan® database were used to estimate the prevalence of overall plaque psoriasis and moderate to severe plaque psoriasis in pediatric patients (aged 6-17 years) from 2016 to 2020. Systemic/phototherapy treatment use (per 100 patient-years [PY]) in moderate to severe pediatric patients was reported from 2017 to 2021.Results: A total of 8935 pediatric patients with psoriasis were included, of whom 1448 had moderate to severe psoriasis. In 2020, the estimated overall pediatric psoriasis prevalence based on coding was 117.4/100,000, and it was 18.4/100,000 for moderate to severe psoriasis. Between 2017 and 2021, the use of non-biologic systemic treatments (2017: 36.3/100 PY; 2021: 14.1/100 PY) and phototherapy treatments (2017: 41.3/100 PY; 2021: 4.3/100 PY) decreased, while the use of biologics increased (2017: 41.5/100 PY; 2021: 56.4/100 PY). Interleukin inhibitor use increased (2017: 5.0/100 PY; 2021: 37.6/100 PY), while tumor necrosis factor (TNF) inhibitor use decreased (2017: 37.5/100 PY; 2021: 20.2/100 PY). Ustekinumab use increased the most (2017: 4.8/100 PY; 2021: 30.4/100 PY), followed by ixekizumab (2017: 0.2/100 PY; 2021: 7.2/100 PY).Conclusions: In 2020, psoriasis remained relatively uncommon among US children and adolescents, with 15.9% having moderate to severe psoriasis. Meanwhile, treatment for moderate to severe psoriasis shifted from older treatments, particularly non-biologic systemics and TNF inhibitors, toward newer, more efficacious interleukin inhibitors.","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":""},"PeriodicalIF":4.2000,"publicationDate":"2025-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Dermatology and Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s13555-025-01545-5","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"DERMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Biologics may have altered the standard of care for pediatric psoriasis, the prevalence of which has not been studied since 2015. The objective of this study was to provide an update of the prevalence of and treatment landscape for pediatric psoriasis in the USA, highlighting the current burden of the condition and the need for improved disease awareness.

Methods: In this retrospective cohort study, US claims data (July 2015 to October 2021) from the MarketScan^® database were used to estimate the prevalence of overall plaque psoriasis and moderate to severe plaque psoriasis in pediatric patients (aged 6-17 years) from 2016 to 2020. Systemic/phototherapy treatment use (per 100 patient-years [PY]) in moderate to severe pediatric patients was reported from 2017 to 2021.

Results: A total of 8935 pediatric patients with psoriasis were included, of whom 1448 had moderate to severe psoriasis. In 2020, the estimated overall pediatric psoriasis prevalence based on coding was 117.4/100,000, and it was 18.4/100,000 for moderate to severe psoriasis. Between 2017 and 2021, the use of non-biologic systemic treatments (2017: 36.3/100 PY; 2021: 14.1/100 PY) and phototherapy treatments (2017: 41.3/100 PY; 2021: 4.3/100 PY) decreased, while the use of biologics increased (2017: 41.5/100 PY; 2021: 56.4/100 PY). Interleukin inhibitor use increased (2017: 5.0/100 PY; 2021: 37.6/100 PY), while tumor necrosis factor (TNF) inhibitor use decreased (2017: 37.5/100 PY; 2021: 20.2/100 PY). Ustekinumab use increased the most (2017: 4.8/100 PY; 2021: 30.4/100 PY), followed by ixekizumab (2017: 0.2/100 PY; 2021: 7.2/100 PY).

Conclusions: In 2020, psoriasis remained relatively uncommon among US children and adolescents, with 15.9% having moderate to severe psoriasis. Meanwhile, treatment for moderate to severe psoriasis shifted from older treatments, particularly non-biologic systemics and TNF inhibitors, toward newer, more efficacious interleukin inhibitors.

查看原文本刊更多论文

2015年至2021年美国儿童牛皮癣全身治疗的患病率和趋势

生物制剂可能已经改变了儿童牛皮癣的护理标准，自2015年以来尚未对其患病率进行研究。本研究的目的是提供美国儿童牛皮癣患病率和治疗前景的最新情况，强调当前该病的负担和提高疾病意识的必要性。方法：在这项回顾性队列研究中，使用来自MarketScan®数据库的美国索赔数据（2015年7月至2021年10月）来估计2016年至2020年6-17岁儿科患者中斑块性银屑病和中度至重度斑块性银屑病的患病率。2017年至2021年报告了中重度儿科患者的全身/光疗治疗使用（每100患者年[PY]）。结果：共纳入8935例小儿牛皮癣患者，其中1448例为中重度牛皮癣。2020年，基于编码估计的儿童牛皮癣总体患病率为117.4/10万，中度至重度牛皮癣患病率为18.4/10万。2017年至2021年间，非生物全身治疗（2017年：36.3/100 PY； 2021年：14.1/100 PY）和光疗治疗（2017年：41.3/100 PY； 2021年：4.3/100 PY）的使用减少，而生物制剂的使用增加（2017年：41.5/100 PY； 2021年：56.4/100 PY）。白细胞介素抑制剂使用量增加（2017年：5.0/100 PY； 2021年：37.6/100 PY），肿瘤坏死因子（TNF）抑制剂使用量减少（2017年：37.5/100 PY； 2021年：20.2/100 PY）。Ustekinumab使用量增加最多（2017年：4.8/100 PY； 2021年：30.4/100 PY），其次是ixekizumab（2017年：0.2/100 PY； 2021年：7.2/100 PY）。结论：2020年，牛皮癣在美国儿童和青少年中仍然相对少见，15.9%的儿童和青少年患有中度至重度牛皮癣。与此同时，中重度牛皮癣的治疗从传统的治疗方法，特别是非生物制剂和TNF抑制剂，转向更新、更有效的白细胞介素抑制剂。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Dermatology and Therapy Medicine-Dermatology

CiteScore

6.00

自引率

8.80%

发文量

187

审稿时长

6 weeks

期刊介绍： Dermatology and Therapy is an international, open access, peer-reviewed, rapid publication journal (peer review in 2 weeks, published 3–4 weeks from acceptance). The journal is dedicated to the publication of high-quality clinical (all phases), observational, real-world, and health outcomes research around the discovery, development, and use of dermatological therapies. Studies relating to diagnosis, pharmacoeconomics, public health and epidemiology, quality of life, and patient care, management, and education are also encouraged. Areas of focus include, but are not limited to all clinical aspects of dermatology, such as skin pharmacology; skin development and aging; prevention, diagnosis, and management of skin disorders and melanomas; research into dermal structures and pathology; and all areas of aesthetic dermatology, including skin maintenance, dermatological surgery, and lasers. The journal is of interest to a broad audience of pharmaceutical and healthcare professionals and publishes original research, reviews, case reports/case series, trial protocols, and short communications. Dermatology and Therapy will consider all scientifically sound research be it positive, confirmatory or negative data. Submissions are welcomed whether they relate to an International and/or a country-specific audience, something that is crucially important when researchers are trying to target more specific patient populations. This inclusive approach allows the journal to assist in the dissemination of quality research, which may be considered of insufficient interest by other journals. The journal appeals to a global audience and receives submissions from all over the world.